
The British government announced it will extend its data management contract with Palantir, the US technology company, through 2029 for use across the National Health Service in England. The £330m agreement, which commenced in 2024 to assist with hospital waiting list management, was originally scheduled to conclude in 2031. Rather than invoking an early exit clause available next year, the government stated it will begin a procurement process next summer to allow domestic firms to compete for the contract starting in 2029.
The decision has drawn criticism from multiple quarters. A House of Commons Committee previously recommended the government terminate its relationship with Palantir in favor of a supplier “more compatible with UK values.” Several Labour MPs expressed disappointment, describing the contract as problematic for the NHS. The Liberal Democrats characterized the arrangement as “dangerous,” while some government members argued the timeframe for transition remained too lengthy. Critics cited concerns about patient data usage and Palantir’s connections to Israeli military operations and US immigration enforcement activities.
Opposition figures, including former shadow chancellor John McDonnell, called for more immediate action to reduce reliance on the company and questioned its human rights practices. Health Minister James Frith defended the government’s position, stating the decision was neither motivated by executive politics nor company clients’ geographic locations. Officials indicated the government would actively encourage UK-based companies to submit bids to prevent excessive dependence on a single supplier.
The British Medical Association, representing physicians, acknowledged the government’s responsiveness to concerns regarding Palantir but expressed frustration over the extended timeline for transitioning to an alternative provider. Palantir UK responded by highlighting its performance achievements, noting the program had surpassed targets in delivering additional surgical procedures, accelerating patient discharge, and reducing waiting times for cancer diagnosis results.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI